Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 8/20 | 0.69 |
| ▸ | HTR1A | P08908 | 6/20 | 0.69 |
| ▸ | HTR2C | P28335 | 4/20 | 0.69 |
| ▸ | HTR2B | P41595 | 3/20 | 0.69 |
| ▸ | HTR6 | P50406 | 6/20 | 0.66 |
| ▸ | BCHE | P06276 | 1/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.61 |
| ▸ | HTR7 | P34969 | 3/20 | 0.56 |
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.56 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.56 |
| ▸ | HRH1 | P35367 | 2/20 | 0.56 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.56 |
| ▸ | HTR1B | P28222 | 2/20 | 0.56 |
| ▸ | CDK4 | P11802 | 1/20 | 0.56 |
| ▸ | CCND1 | P24385 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23042909 | 0.98 | HTR2A (0.71) | HTR2AHTR1AHTR2CHTR2BHTR6 | |
| SCHEMBL30896267 | 0.92 | HTR2A (0.81) | HTR2AHTR1AHTR2CHTR2BHTR6 | |
| SCHEMBL21073587 | 0.90 | HTR2A (0.68) | HTR2AHTR1AHTR2CHTR2BHTR6 | |
| SCHEMBL29504149 | 0.88 | HTR1A (0.74) | HTR2AHTR1AHTR2CHTR2BHTR6 | |
| SCHEMBL20970920 | 0.88 | HTR1A (0.74) | HTR2AHTR1AHTR2CHTR2BHTR6 | |
| SCHEMBL17518864 | 0.85 | HTR1A (0.69) | HTR2AHTR1AHTR2CHTR2BHTR6 | |
| SCHEMBL1118996 | 0.84 | HTR2A (0.88) | HTR2AHTR1AHTR2CHTR2BHTR6 | |
| SCHEMBL10649896 | 0.82 | HTR2A (0.66) | HTR2AHTR1AHTR2CHTR2BHTR6 | |
| SCHEMBL25885220 | 0.82 | HTR1A (0.66) | HTR2AHTR1AHTR2CHTR2BHTR6 | |
| N,N-Dimethyltryptamine SCHEMBL335710 | 0.82 | HTR2A (1.00) | HTR2AHTR1AHTR2CHTR2BHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497361-B2 | Crystalline tryptamine compounds | CAAMTECH, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| US-20240409513-A1 | CRYSTALLINE TRYPTAMINE COMPOUNDS | CAAMTECH, INC. | 2024-12-12 | — | — | US | disclosed |
| US-20240409513-A1 | CRYSTALLINE TRYPTAMINE COMPOUNDS | CAAMTECH, INC. | 2024-12-12 | — | — | US | disclosed |
| EP-4415710-A1 | CRYSTALLINE TRYPTAMINE COMPOUNDS | Caamtech, Inc. (US) | 2024-08-21 | — | — | EP | disclosed |
| WO-2023064840-A1 | CRYSTALLINE TRYPTAMINE COMPOUNDS | CAAMTECH, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12497361-B2 | Crystalline tryptamine compounds | TPH1, HTR5A, TPH2 | HTR2A 14/4885HTR1A 7/4885HTR2C 9/4885 |
| US-20240409513-A1 | CRYSTALLINE TRYPTAMINE COMPOUNDS | TPH1, HTR5A, TPH2 | HTR2A 9/4885HTR1A 7/4885HTR2C 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.